Ocuphire Pharma Investor Day Presentation Deck

RM 48 MIRA Program Evaluating Nyxol for the Reversal of Mydriasis Efficient Clinical Programs have Positioned Ocuphire to Target NDA Filing in Late 2022 MIRA-1 2019 Phase 2b n=32 crossover Ocuphire Primary Endpoint Met ✓ Secondary Endpoints Met ✓ MIRA-2 2021 Phase 3 n=185 Primary Endpoint Met ✓ Secondary Endpoints Met ✓ MIRA-3 2022 Phase 3 n=330 MIRA-4 2022 Pediatric Safety n=20 RM NDA Filing 2022 NDA Submission Ocuphire PHARMA

View entire presentation